Authors

Benjamin P. Levy, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Benjamin P. Levy, MD, Mount Sinai

Benjamin P. Levy, MD, Mount Sinai Health Systems

Benjamin P. Levy, MD, Mount Sinai Hospital

Benjamin P. Levy, MD, Sibley Memorial Hospital

Latest:

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Benjamin Powers, MD

Latest:

Focusing on Your Patient's Needs

Although the ever-expanding list of targeted drugs, and the seemingly relentless stack of evidence-based trials are daunting, the toughest yet most important lesson to me so far is to realize when doing everything is not warranted, necessary, desired, or feasible.

Benjamin R. Lee, MD

Latest:

Dr. Lee on Nanotechnology Combination Therapy in RCC

Benjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).

Benjamin Weinberg, MD

Latest:

Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC

Benjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.

Benny Weksler, MD

Latest:

Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLC

Benny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally-invasive surgery in the stages of non–small cell lung cancers (NSCLC).

Benoit You, MD, PhD

Latest:

Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors

Benoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.

Bernard A. Fox, PhD

Latest:

Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck Cancer

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Bernard H. Bochner, MD, FACS

Latest:

Dr Bochner on the Need for Multimodal Approaches in MIBC

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Bernard J. Escudier, MD

Latest:

Dr. Escudier on Patients Preferring Pazopanib for mRCC

Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.

Bernardo L. Rapoport, MD

Latest:

Dr. Rapoport on Rolapitant for the Prevention of CINV

Bernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).

Bernd Kasper, MD, PhD

Latest:

Dr Kasper on the FDA Approval of Nirogacestat in Desmoid Tumors

Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.

Bert H. O'Neil, MD

Latest:

Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRC

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Bert H. ONeil, MD, Indiana University School of Medicine

Bert O'Neil

Latest:

Dr. O'Neil on Left-Sided Versus Right-Sided CRC

Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).

Bert O'Neil, MD

Latest:

Dr. O'Neil on Neuroendocrine Tumors

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Bertram Yuh, MD

Latest:

Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate Cancer

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.